Related references
Note: Only part of the references are listed.Improved glycemic control in mice lacking Sglt1 and Sglt2
David R. Powell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen (Jim) Liu et al.
DIABETES (2012)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
L. Zhang et al.
DIABETES OBESITY & METABOLISM (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels:: Involvement of hepatocyte nuclear factor-1α expression and activity
H. S. Freitas et al.
ENDOCRINOLOGY (2008)
Determining 'true' glomerular filtration rate in healthy adults using infusion of inulin and comparing it with values obtained using other clearance techniques or prediction equations
G. Sterner et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2008)
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
Kenji Katsuno et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Medical progress - Assessing kidney function - Measured and estimated glomerular filtration rate
Lesley A. Stevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane
J Marks et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)
Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats
WT Noonan et al.
LIFE SCIENCES (2001)